Futures Up, Dell Fl...
Health Care: Drugs
Savient Pharmaceuticals (SVNT: NASDAQ)
$0.56 -0.01 | -1.75%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -118.31M | -102.03M | -73.11M | -90.85M |
| Operating Gains/Losses | -21.80M | 9.00K | 0.00 | -182.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 396.00K | -3.83M | 1.45M | 3.99M |
| (Increase) Decrease in Inventories | 6.60M | -7.78M | -2.56M | 1.31M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -3.61M | 5.44M | -6.31M | 2.03M |
| (Decrease) Increase In Other Current Liabilities | 2.14M | 6.58M | 3.55M | -4.61M |
| (Increase) Decrease In Other Working Capital | 1.74M | -6.07M | 355.00K | -378.00K |
| Other Non-Cash Items | 4.58M | 4.58M | 20.47M | 14.54M |
| Net Cash From Continuing Operations | -114.74M | -116.84M | -52.38M | -69.64M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -114.74M | -116.84M | -52.38M | -69.64M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 66.45M | 30.41M | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.68M | -416.00K | -234.00K | -71.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -56.70M | -66.04M | -20.07M | 0.00 |
| Other Cash from Investing Activities | 150.00K | -1.30M | 11.00K | 10.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 8.22M | -37.34M | -20.29M | 4.08M |
| Issuance of Debt | 42.65M | 222.70M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 502.00K | 803.00K | 10.63M | 97.48M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -60.00K | -66.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | -1.28M | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | -35.00K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 43.15M | 223.46M | 9.29M | 97.42M |
| Effect of Exchange Rate Changes | -383.00K | 15.00K | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -63.76M | 69.30M | -63.38M | 31.86M |
Portfolios with SVNT
- Portfolio NameUser Type
- Usertest1123
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- Contributor10 Stocks That Could Rise i...
- Contributor13 Biotech Stocks Bought an...
- Contributor10 Most Shorted Stocks in B...
Latest SVNT Headlines from TheStreet
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- Lessons From Biotech's Best Third Quarter Stocks 10.02.12 | 09:10 am
- Savient Bulls Come Back for More 09.19.12 | 05:09 am
- 5 Stocks Under $10 Set to Soar 08.16.12 | 01:08 pm
- 5 Stocks Poised for Breakouts 08.10.12 | 01:08 pm
- Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.08.12 | 01:08 pm
- Juicy Details From Tang Capital's Lawsuit Against Savient Pharma 05.01.12 | 03:05 pm
- Biotech Stock Mailbag: Amarin 04.23.12 | 07:04 am
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
- Savient Stock Hits New 52-Week Low (SVNT) 03.02.12 | 12:03 pm
Press Releases for SVNT
- Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization For The Treatment Of Certain Patients With Chronic Tophaceous Gout - PR Newswire 01.08.13 | 11:01 am
- Savient Pharmaceuticals To Present At The 31st Annual J.P. Morgan Healthcare Conference - PR Newswire 01.04.13 | 08:01 am
- Savient Receives Positive CHMP Opinion For KRYSTEXXA® Approval In The EU - PR Newswire 10.19.12 | 10:10 am
- Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer - PR Newswire 09.24.12 | 07:09 am
- Analysis Of KRYSTEXXA® Phase III Data Demonstrates Improved Health-Related Quality Of Life And Physical Function In Refractory Chronic Gout Patients - PR Newswire 07.02.12 | 08:07 am
- Savient Pharmaceuticals Completes Financing And Debt Restructuring Transactions - PR Newswire 05.09.12 | 03:05 pm
- Savient Pharmaceuticals And Jim Belushi Launch "Check Out Your Gout" Educational Campaign - PR Newswire 11.07.11 | 08:11 am
- Savient Pharmaceuticals Announces Publication Of Pivotal Phase III KRYSTEXXA® Data In JAMA Demonstrating Significant Benefits In Refractory Chronic Gout Patients - PR Newswire 08.16.11 | 04:08 pm
- Savient Pharmaceuticals To Present At The Wedbush Securities 2011 Life Sciences Management Access Conference - PR Newswire 08.10.11 | 04:08 pm
- Savient Pharmaceuticals To Hold Second Quarter 2011 Financial Results Conference Call On Thursday, August 4, 2011 - PR Newswire 07.20.11 | 04:07 pm
Partner Headlines for SVNT
- Perrigo expands UK presence - Financial Times 02.11.13 | 05:02 pm
- OCZ Tech: Untouchable For Now - Seeking Alpha 10.11.12 | 09:10 am
- 3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out - Seeking Alpha 09.17.12 | 09:09 am
- 5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year - Seeking Alpha 08.28.12 | 09:08 am
- Benzinga's Microcap Movers for Friday August 24, 2012 - Benzinga 08.26.12 | 09:08 am
- Healthcare Business Review: Savient's Favorable RULING, Forest Gets FDA OKAY - Wall St. Cheat Sheet 07.24.12 | 08:07 am
- Savient Gets New CEO, Cuts Jobs - Analyst Blog - Zacks 07.10.12 | 07:07 pm
- Savient Pharmaceuticals Note Holders Claim Default -8K - Benzinga 06.09.12 | 08:06 am
- 2 Biotech Stocks To Consider Now, 1 To Avoid - Seeking Alpha 04.10.12 | 09:04 am
- VIX - Options Volatility Sonar: Friday Recap - Seeking Alpha 03.16.12 | 05:03 pm
